

GLAXOSMITHKLINE PLC

Form 6-K

July 25, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 25 July 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Sir Philip Hampton
 - b) Position/status Non-Executive Chairman
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 April 2018 to 30 June 2018.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.57	2,809.891
 - d) Aggregated information n/a (single transaction)
 - e) Aggregated volume Price
 - e) Date of the transaction 2018-07-25
 - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr Vindi Banga
 - b) Position/status Senior Independent Non-Executive Director
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 April 2018 to 30 June 2018.
- c) Price(s) and volume(s) Price(s) Volume(s)
£15.57 461.625
- d) Aggregated information n/a (single transaction)
- e) Date of the transaction Aggregated volume Price
2018-07-25
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Dr Vivienne Cox
b) Position/status Independent Non-Executive Director
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

April 2018 to 30 June 2018.

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.57	341.201
Aggregated information		
d)	n/a (single transaction)	
Aggregated volume Price		
e) Date of the transaction	2018-07-25	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms Lynn Elsenhans
b) Position/status	Independent Non-Executive Director
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
--	---

b) Nature of the transaction	Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 April 2018 to 30 June 2018.
------------------------------	---

c) Price(s) and volume(s)	Price(s)	Volume(s)
	\$41.34	1,203.681
Aggregated information		
d)	n/a (single transaction)	
Aggregated volume Price		
e) Date of the transaction	2018-07-25	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Dr Laurie Glimcher
b) Position/status	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

	Independent Non-Executive Director
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b) Nature of the transaction	Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 April 2018 to 30 June 2018.
c) Price(s) and volume(s)	Price(s) Volume(s) \$41.34 1,329.780
d) Aggregated information	
e) Date of the transaction	2018-07-25
f) Place of the transaction	n/a
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Dr Jesse Goodman
b) Position/status	Independent Non-Executive Director
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b) Nature of the transaction	Acquisition of notional ADSs under the share allocation

arrangements for Independent Non-Executive Directors for the period of service from 1 April 2018 to 30 June 2018.

c) Price(s) and volume(s)	Price(s)	Volume(s)
Aggregated information	\$41.34	470.009
d) Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2018-07-25	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms Judy Lewent
 - b) Position/status Independent Non-Executive Director
 - c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053

- b) Nature of the transaction Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 April 2018 to 30 June 2018.

c) Price(s) and volume(s)	Price(s)	Volume(s)
Aggregated information	\$41.34	515.863
d) Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2018-07-25	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- | | |
|---|--|
| a) Name | Mr Urs Rohner |
| b) Position/status | Independent Non-Executive Director |
| c) Initial notification/
amendment | Initial notification |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |
| 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
| b) Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 April 2018 to 30 June 2018. |
| c) Price(s) and volume(s) | Price(s) Volume(s)
£15.57 461.625 |
| Aggregated information | |
| d) Aggregated volume Price | n/a (single transaction) |
| e) Date of the transaction | 2018-07-25 |
| f) Place of the transaction | n/a |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: July 25, 2018

By: VICTORIA WHYTE

Victoria Whyte

Authorised Signatory for and on
behalf of GlaxoSmithKline plc